Security Snapshot

SANGAMO THERAPEUTICS, INC - Common Stock, $0.01 par value per share (SGMO) Institutional Ownership

CUSIP: 800677106

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

106

Shares (Excl. Options)

103,474,681

Price

$0.25

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock, $0.01 par value per share
Symbol
SGMO on OTC
Shares outstanding
414,359,662
Price per share
$0.13
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
103,474,681
Total reported value
$25,552,747
% of total 13F portfolios
0%
Share change
+39,540,253
Value change
+$8,106,512
Number of holders
106
Price from insider filings
$0.13
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • SGMO - SANGAMO THERAPEUTICS, INC - Common Stock, $0.01 par value per share is tracked under CUSIP 800677106.
  • 106 institutions reported positions in Q1 2026.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 104 to 106 between Q4 2025 and Q1 2026.
  • Reported value moved from $26,151,849 to $25,552,747.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 106 institutions filings for Q1 2026.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 800677106?
CUSIP 800677106 identifies SGMO - SANGAMO THERAPEUTICS, INC - Common Stock, $0.01 par value per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.

Significant Owners of SANGAMO THERAPEUTICS, INC - Common Stock, $0.01 par value per share (SGMO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARMISTICE CAPITAL, LLC 9.8% $10,504,017 40,400,067 Armistice Capital, LLC 31 Mar 2026
WASATCH ADVISORS LP 2.1% -62% $4,167,240 -$3,664,854 6,188,358 -47% Wasatch Advisors LP 30 Sep 2025

As of 31 Mar 2026, 106 institutional investors reported holding 103,474,681 shares of SANGAMO THERAPEUTICS, INC - Common Stock, $0.01 par value per share (SGMO). This represents 25% of the company’s total 414,359,662 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of SANGAMO THERAPEUTICS, INC - Common Stock, $0.01 par value per share (SGMO) together control 24% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ARMISTICE CAPITAL, LLC 9.7% 40,400,067 0.33% $9,974,777
VANGUARD CAPITAL MANAGEMENT LLC 3.1% 12,704,408 0% 0% $3,137,989
TWO SIGMA INVESTMENTS, LP 1.5% 6,270,441 +32% 0% $1,548,172
Balyasny Asset Management L.P. 1.3% 5,288,097 0% $1,305,631
GEODE CAPITAL MANAGEMENT, LLC 1.1% 4,570,862 +18% 0% $1,128,972
BlackRock, Inc. 1.1% 4,547,848 -0.52% 0% $1,122,863
RENAISSANCE TECHNOLOGIES LLC 0.93% 3,836,665 -54% 0% $947,273
UBS Group AG 0.62% 2,570,992 +151% 0% $635,035
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.57% 2,352,360 +37% 0% $580,798
VANGUARD FIDUCIARY TRUST CO 0.56% 2,310,297 0% 0% $570,643
JACOBS LEVY EQUITY MANAGEMENT, INC 0.49% 2,050,384 +95% 0% $506,240
STATE STREET CORP 0.41% 1,694,783 +25% 0% $418,442
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.41% 1,687,463 -21% 0% $416,634
LUMINUS MANAGEMENT LLC 0.41% 1,681,089 +45% 0.25% $415,061
Ikarian Capital, LLC 0.29% 1,218,671 0% 0.04% $300,890
Invesco Ltd. 0.25% 1,045,232 +4.5% 0% $258,068
NORTHERN TRUST CORP 0.18% 737,867 0% 0% $182,179
HighTower Advisors, LLC 0.17% 706,481 +0.29% 0% $174,431
SANDERS MORRIS HARRIS LLC 0.16% 668,000 0.03% $164,929
MAK CAPITAL ONE LLC 0.14% 561,538 0.02% $138,644
MORGAN STANLEY 0.1% 423,265 -0.11% 0% $104,504
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 0.1% 400,000 0% 0% $99,000
CANADA PENSION PLAN INVESTMENT BOARD 0.1% 397,100 +58% 0% $98,044
GOLDMAN SACHS GROUP INC 0.09% 377,287 +98% 0% $93,152
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 0.09% 361,277 +3.8% 0% $89,199

Institutional Holders of SANGAMO THERAPEUTICS, INC - Common Stock, $0.01 par value per share (SGMO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 103,474,681 $25,552,747 +$8,106,512 $0.25 106
2025 Q4 62,261,277 $26,151,849 -$866,572 $0.42 104
2025 Q3 62,601,923 $42,143,656 -$4,085,084 $0.67 112
2025 Q2 73,226,420 $39,627,128 -$1,366,580 $0.54 110
2025 Q1 52,557,554 $34,474,526 -$6,973,632 $0.66 118
2024 Q4 61,547,249 $62,817,305 +$5,840,058 $1.02 125
2024 Q3 55,892,914 $48,377,748 -$13,237,737 $0.87 100
2024 Q2 86,880,740 $31,098,958 -$5,513,248 $0.36 126
2024 Q1 100,425,667 $67,257,419 +$9,590,265 $0.67 125
2023 Q4 86,966,421 $47,198,697 -$9,265,269 $0.54 129
2023 Q3 102,314,735 $61,341,591 -$4,250,211 $0.60 131
2023 Q2 105,778,869 $137,125,383 -$10,782,201 $1.30 149
2023 Q1 112,297,853 $197,560,841 +$11,997,591 $1.76 178
2022 Q4 104,011,293 $326,153,436 +$18,050,138 $3.14 179
2022 Q3 97,395,258 $477,415,251 +$38,514,658 $4.90 189
2022 Q2 89,662,495 $371,001,039 +$44,113,066 $4.14 174
2022 Q1 79,972,857 $465,159,583 +$13,325,276 $5.81 184
2021 Q4 76,880,593 $576,854,799 +$14,652,510 $7.50 178
2021 Q3 75,230,827 $678,917,887 -$11,341,782 $9.01 182
2021 Q2 76,183,727 $911,820,230 -$39,619,833 $11.97 189
2021 Q1 79,366,997 $993,813,520 +$8,744,496 $12.53 189
2020 Q4 78,279,519 $1,221,988,081 -$2,887,670 $15.60 215
2020 Q3 81,633,901 $772,262,574 +$39,692,524 $9.45 203
2020 Q2 77,064,448 $690,282,893 +$38,360,714 $8.96 197
2020 Q1 74,003,681 $471,429,640 -$44,160,048 $6.37 175
2019 Q4 78,484,613 $656,787,904 -$35,488,595 $8.37 187
2019 Q3 82,109,589 $743,984,330 +$18,180,888 $9.05 178
2019 Q2 79,874,675 $860,158,811 +$188,076,135 $10.77 178
2019 Q1 65,891,322 $628,583,823 +$8,491,929 $9.54 178
2018 Q4 63,962,974 $734,063,851 -$24,514,588 $11.48 189
2018 Q3 64,628,739 $1,095,486,294 +$6,279,681 $16.95 214
2018 Q2 64,727,770 $919,122,586 +$101,709,560 $14.20 206
2018 Q1 57,191,865 $1,086,683,045 +$32,050,241 $19.00 205
2017 Q4 55,555,574 $911,135,543 +$36,567,117 $16.40 167
2017 Q3 54,652,539 $819,732,570 +$37,421,908 $15.00 147
2017 Q2 53,038,835 $466,764,979 +$100,856,480 $8.80 143
2017 Q1 41,889,756 $217,701,771 +$36,392,442 $5.20 115
2016 Q4 41,299,445 $125,949,665 -$12,015,817 $3.05 120
2016 Q3 43,952,613 $203,488,438 -$12,236,220 $4.63 121
2016 Q2 46,220,859 $267,610,930 -$15,550,987 $5.79 136
2016 Q1 48,689,873 $292,366,107 -$4,019,351 $6.05 142
2015 Q4 49,096,342 $448,268,385 -$26,270,998 $9.13 139
2015 Q3 52,669,346 $297,043,899 -$28,205,503 $5.64 140
2015 Q2 50,554,743 $560,557,135 -$37,822,320 $11.09 156
2015 Q1 52,645,653 $825,232,264 +$55,231,033 $15.68 167
2014 Q4 49,165,950 $747,418,239 +$7,297,640 $15.21 157
2014 Q3 48,823,503 $526,594,567 -$9,059,452 $10.78 157
2014 Q2 48,883,624 $746,320,055 -$18,445,491 $15.27 154
2014 Q1 48,216,512 $871,455,782 +$52,843,003 $18.08 144
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .